Sophrology Treatment for Patients With Glial Tumours Requiring Speech Therapy
Launched by INSTITUT CANCEROLOGIE DE L'OUEST · Dec 28, 2021
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a technique called sophrology combined with speech therapy for patients who have certain types of brain tumors known as glial tumors. These patients often face challenges with communication and experience high levels of anxiety and depression, which can significantly affect their quality of life. The researchers believe that using sophrology, a method that promotes relaxation and mental well-being, along with traditional speech therapy could help improve patients' anxiety levels, overall quality of life, and ability to communicate.
To be eligible for this trial, participants must be at least 18 years old, have a confirmed diagnosis of a grade III or IV glial tumor, and need speech therapy. They should also be willing to start outpatient speech therapy and be able to commit to the study's requirements, including filling out questionnaires and attending sessions. Participants will have the opportunity to explore the benefits of both sophrology and speech therapy while being closely monitored for their progress throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with histologically proven grade III and IV glial tumours requiring speech therapy;
- • Patient willing to start outpatient speech therapy;
- • Patient aged 18 years and over;
- • Informed patient who has signed consent;
- • Patient affiliated to a social security scheme.
- Exclusion Criteria:
- • Patient who has already had an initiation to sophrology in the context of his pathology;
- • PS ≥ 4 ;
- • Patients suffering from psychiatric disorders; delusional phases, schizophrenia against the practice of sophrology;
- • Patient unable to follow the protocol (filling in questionnaires, attendance of sophrology and/or speech therapy sessions) for geographical, social or psychological reasons;
- • Patients who do not speak French;
- • Persons deprived of their liberty, under court protection, under curators or under the authority of a guardian.
- • Women who are pregnant, likely to be pregnant or breastfeeding;
About Institut Cancerologie De L'ouest
The Institut de Cancérologie de l'Ouest (ICO) is a leading French cancer research and treatment center dedicated to advancing oncology through innovative clinical trials and multidisciplinary care. As a key player in the fight against cancer, ICO integrates cutting-edge research with clinical practice, focusing on personalized medicine and patient-centered approaches. With a commitment to improving patient outcomes, ICO collaborates with academic institutions and industry partners to develop novel therapies and enhance understanding of cancer biology. The institute's expertise spans various cancer types, making it a pivotal hub for oncological research and education in France and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Herblain, , France
Patients applied
Trial Officials
CELINE THOMAS
Principal Investigator
Institut de Cancérologie de l'Ouest
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials